FIGURE 3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Expression of protein markers significantly altered by treatment with eribulin in combination with copanlisib in all PDX models. A, Expression of RPPA protein markers significantly altered, with FDR-adjusted P value <0.1, comparing treatment with the combination of eribulin and copanlisib versus vehicle are shown for individual tumors from each PDX model at the completion of 3–4 weeks of treatment with either vehicle, eribulin, copanlisib, or eribulin plus copanlisib. Note that WHIM34 and WHIM29 tumors treated with eribulin or eribulin in combination with copanlisib were missing in the analysis due to insufficient quantity of tumors at the completion of treatment. B, Heat map of estimated coefficient for FDR significantly altered markers (P < 0.1) comparing copanlisib plus eribulin versus vehicle.